Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy.

Jingjing Wang, Jie Tan, Bian Wu, Ruolin Wu, Yanmei Han, Chenyang Wang, Zairong Gao, Dawei Jiang, Xiaotian Xia

Journal: Journal of nanobiotechnology 2023;21(1):374

PMID: 37833748

Free Full Text on BioMed Central View on PubMed

Abstract

Anaplastic thyroid cancer (ATC) is a rare but highly aggressive kind of thyroid cancer. Various therapeutic methods have been considered for the treatment of ATC, but its prognosis remains poor. With the advent of the nanomedicine era, the use of nanotechnology has been introduced in the treatment of various cancers and has shown great potential and broad prospects in ATC treatment. The current review meticulously describes and summarizes the research progress of various nanomedicine-based therapeutic methods of ATC, including chemotherapy, differentiation therapy, radioiodine therapy, gene therapy, targeted therapy, photothermal therapy, and combination therapy. Furthermore, potential future challenges and opportunities for the currently developed nanomedicines for ATC treatment are discussed. As far as we know, there are few reviews focusing on the nanomedicine of ATC therapy, and it is believed that this review will generate widespread interest from researchers in a variety of fields to further expedite preclinical research and clinical translation of ATC nanomedicines.

Address: Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, 430022, Wuhan, Hubei, PR China.; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China.; Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, China.; Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, 430022, Wuhan, Hubei, PR China. [email protected].; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. [email protected].; Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, China. [email protected].; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, 430022, Wuhan, Hubei, PR China. [email protected].; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. [email protected].; Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, China. [email protected].; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, 430022, Wuhan, Hubei, PR China. [email protected].; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. [email protected].; Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, China. [email protected].

DOI: 10.1186/s12951-023-02094-9

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/thyroidcancer.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-ATM-4

MeSH Terms: Humans, Thyroid Carcinoma, Anaplastic, Iodine Radioisotopes, Thyroid Neoplasms, Combined Modality Therapy, Prognosis